Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
1 study found for:    NCT01074970
Show Display Options
Rank Status Study
1 Active, not recruiting PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 Mutations
Condition: Breast Cancer
Interventions: Drug: Cisplatin;   Drug: Rucaparib

Study has passed its completion date and status has not been verified in more than two years.